to continued From during Thank you, advancements an Martina, quarter. Insmed good operational and the everyone. morning, important second make perspective,
quarter, and the Europe during commercial launched global the Japan. has footprint U.S., and in Our expanded ARIKAYCE now
of vary, delta the of are markets. the of we encouraged in will impact by the each potential these While globally variant ARIKAYCE
Our current Starting growth ARIKAYCE ARIKAYCE in were early during performance the signs as with efforts business. preliminary Europe. our with quarter. of our second in the U.S. pleased U.S. reflect solid as sales positive We well
the We shifting generally eye than where continue to rates southern other keep COVID-XX and see variability regional are landscape, vaccination in the the particularly close a lower where on states we in visits. main physician to regions. patients We in-person accelerated anticipate our offices will U.S. drivers: and therapeutic growth return reopening; the in-office by X field; in ARIKAYCE be the of specialists returning
field the achieved solid are specialists engagement. largely therapeutic and Our customer in have back
end physician in across U.S. majority steady the person by the return specialists. interactions the interactions were are U.S., persists While the of in the Across with regional we centers to these therapeutic our variability encouraged in-person as June. of of
in-person almost large our a toward willing trained that of This XX an population, vaccinated. is returning of the fully equally we patient by XX% represents and We number a hope aged in-person CDC encouraged trainers seen trend we increasing data their older vaccinations visits their return of with program, beneficial. seeing will indicating greater ARIKAYCE to We've peer-to-peer growing which with a number lead U.S. trends physicians. to to that the similar and increased in are are be patients also to in patients with speaker of a proportion patients programs, We're ARIKAYCE home. think
are commercial patients. shipped first in month, Our was Last now Japan to underway. efforts our product
for with close about optimistic currently pursuing, the are is opportunity to population, are the market the refractory Japan, of territories global largest MAC excited as very equally patient this We second. we milestone which, about a in U.S. and be the estimated the
We have to quarters. manage in team challenging I'm launch the excited physicians in working Japan challenges see positive on these providing in future are actively and Japan seen forward updates environment. to to manage several through patients this you from very who our signs look
French The make we date, ARIKAYCE have secure To also Our go to successfully also by ATU country Germany we reimbursement. and reimbursement the in launch and Netherlands. to program. launch as progress we to secured is government of underway, in continue Europe and agreed the extend country
turn Italy efforts the reimbursement securing Ireland, to Our now in U.K. and France.
me a technical to our moment address operations. Let take
where in are We producing territories available, to to continue products a strong demand we all drug ARIKAYCE commercially and position. ARIKAYCE is benefit inventory support from X
X territories in growth we Will. footprint. available our our employee global respect call to As operate has trials TPIP, progress ongoing base, we With continue product manufacturing have across the and support tremendous to and major closing, back throughout approved product. of expansion the ARIKAYCE, on with second now seen we turn our made by In lead brensocatib incredible Insmed to clinical footing quarter. during I'll organization, globe, supply programs, our for product around solid the revenue and marked clinical marketing now
